Literature DB >> 8935410

Molecular study on the infantile form of Pompe disease in Chinese in Taiwan.

C Y Lin1, J J Shieh.   

Abstract

Glycogen-storage disease type II, Pompe disease, is caused by the deficiency of acid alpha-D-glucosidase in lysosome. Previously we found that acid alpha-D-glucosidase did exist in the skin fibroblasts and there was also no difference of mRNA in quantity and size of Chinese infantile type Pompe disease patients in Taiwan. However, functional assay of the acid alpha-D-glucosidase of these patients showed its enzyme function to be defective. In the present study, first we identified a substitution site in four Chinese infantile patients with Pompe disease which is a cytidine to adenosine (C1935-->A) transversion at 5' end of exon 14 causing substitution of glutamic acid for aspartic acid at position 645 of the acid alpha-D-glucosidase. This substitution was introduced in wild-type cDNA and expressed in COS-1 cells. The Asp-645-->Glu substitution resulted in significant reduction of acid alpha-D-glucosidase activity. Second, according to the screening data in 25 Chinese Pompe disease patients using digestion of RT-PCR amplified specific fragment with Aat II, the restriction fragment length analysis showed that patients presented the 861 bp band and the normal individuals presented the 728 bp and 133 bp polymorphic bands. We found that the frequency of mutant allele is 0.8 in infantile patients with Chinese Pompe disease and 0 in normal individuals. These results therefore indicate that Asp-645-->Glu mutation results in infantile form of Pompe disease as the major cause in Chinese patients in Taiwan.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935410

Source DB:  PubMed          Journal:  Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi        ISSN: 0001-6578


  7 in total

1.  Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Authors:  L Wan; C-C Lee; C-M Hsu; W-L Hwu; C-C Yang; C-H Tsai; F-J Tsai
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

2.  Infantile Pompe disease: A case report and review of the Chinese literature.

Authors:  Yun Liu; Yang Yang; Beibei Wang; Lizhi Wu; Honglu Liang; Qing Kan; Zhaolan Cao; Youyan Zhao; Xiaoyu Zhou
Journal:  Exp Ther Med       Date:  2015-11-12       Impact factor: 2.447

3.  A novel homozygous mutation at the GAA gene in Mexicans with early-onset Pompe disease.

Authors:  Carmen Esmer; Rosario Becerra-Becerra; Claudia Peña-Zepeda; Antonio Bravo-Oro
Journal:  Acta Myol       Date:  2013-10

4.  Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology.

Authors:  Elisa Goina; Paolo Peruzzo; Bruno Bembi; Andrea Dardis; Emanuele Buratti
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

5.  Broad variation in phenotypes for common GAA genotypes in Pompe disease.

Authors:  Monica Y Niño; Stijn L M In't Groen; Douglas O S de Faria; Marianne Hoogeveen-Westerveld; Hannerieke J M P van den Hout; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2021-09-08       Impact factor: 4.700

6.  A review of treatment of Pompe disease in infants.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  Biologics       Date:  2007-09

7.  Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center.

Authors:  Min-Sun Kim; Ari Song; Minji Im; June Huh; I-Seok Kang; Jinyoung Song; Aram Yang; Jinsup Kim; Eun-Kyung Kwon; Eu-Jin Choi; Sun-Ju Han; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Korean J Pediatr       Date:  2018-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.